Industry Research Reports
Home > Reports > Pharma & Healthcare > Global Varicella Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
Global Varicella Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
Industry: Pharma & Healthcare
Published Date: 2025-03-19
Pages: 77 Pages
Report ld: 4677408
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Varicella Vaccine Market Size(US$)
CAGR 2025-2031
7.8%
Market Size,2031
USD 8,137
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 5,185 million
Market Forecast in 2031(Value)
US$ 8,137 million
CAGR
7.8%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Varicella Vaccine market size was US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Global Varicella Vaccine key players include Merck, Shanghai Institute, Changsheng, Keygen, GSK, etc.
Asia is the largest market, with a share over 35%, followed by US and Europe, both have a share over 55%.
In terms of product, Freeze-Dried Powder is the largest segment, with a share over 50%. And in terms of application, the largest application is Kids Injection, followed by Adults Injection, etc.
The global Varicella Vaccine market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2020-2031.
MARKET SEGMENTATION
By Company
- Merck
- GSK
- Shanghai Institute
- BCHT
- Changsheng
- Keygen
- Green Cross
- Biken
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Injection
- Freeze-Dried Powder
Segment by Application
- Kids Injection
- Adults Injection
CHAPTER OUTLINE
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Varicella Vaccine market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Freeze-Dried Powder in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Adults Injection in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled Market Entry: Navigate regulatory complexities in focus markets (e.g., China’s policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., Injection dominance in Europe vs. Freeze-Dried Powder demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Market Overview
1.1 Varicella Vaccine Product Scope
1.2 Varicella Vaccine by Type
1.2.1 Global Varicella Vaccine Sales by Type (2020 & 2024 & 2031)
1.2.2 Injection
1.2.3 Freeze-Dried Powder
1.3 Varicella Vaccine by Application
1.3.1 Global Varicella Vaccine Sales Comparison by Application (2020 & 2024 & 2031)
1.3.2 Kids Injection
1.3.3 Adults Injection
1.4 Global Varicella Vaccine Market Estimates and Forecasts (2020-2031)
1.4.1 Global Varicella Vaccine Market Size in Value Growth Rate (2020-2031)
1.4.2 Global Varicella Vaccine Market Size in Volume Growth Rate (2020-2031)
1.4.3 Global Varicella Vaccine Price Trends (2020-2031)
1.5 Assumptions and Limitations
2 Market Size and Prospective by Region
2.1 Global Varicella Vaccine Market Size by Region: 2020 VS 2024 VS 2031
2.2 Global Varicella Vaccine Retrospective Market Scenario by Region (2020-2025)
2.2.1 Global Varicella Vaccine Sales Market Share by Region (2020-2025)
2.2.2 Global Varicella Vaccine Revenue Market Share by Region (2020-2025)
2.3 Global Varicella Vaccine Market Estimates and Forecasts by Region (2026-2031)
2.3.1 Global Varicella Vaccine Sales Estimates and Forecasts by Region (2026-2031)
2.3.2 Global Varicella Vaccine Revenue Forecast by Region (2026-2031)
2.4 Major Region and Emerging Market Analysis
2.4.1 North America Varicella Vaccine Market Size and Prospective (2020-2031)
2.4.2 Europe Varicella Vaccine Market Size and Prospective (2020-2031)
2.4.3 China Varicella Vaccine Market Size and Prospective (2020-2031)
2.4.4 Japan Varicella Vaccine Market Size and Prospective (2020-2031)
2.4.5 South Korea Varicella Vaccine Market Size and Prospective (2020-2031)
3 Global Market Size by Type
3.1 Global Varicella Vaccine Historic Market Review by Type (2020-2025)
3.1.1 Global Varicella Vaccine Sales by Type (2020-2025)
3.1.2 Global Varicella Vaccine Revenue by Type (2020-2025)
3.1.3 Global Varicella Vaccine Price by Type (2020-2025)
3.2 Global Varicella Vaccine Market Estimates and Forecasts by Type (2026-2031)
3.2.1 Global Varicella Vaccine Sales Forecast by Type (2026-2031)
3.2.2 Global Varicella Vaccine Revenue Forecast by Type (2026-2031)
3.2.3 Global Varicella Vaccine Price Forecast by Type (2026-2031)
3.3 Different Types Varicella Vaccine Representative Players
4 Global Market Size by Application
4.1 Global Varicella Vaccine Historic Market Review by Application (2020-2025)
4.1.1 Global Varicella Vaccine Sales by Application (2020-2025)
4.1.2 Global Varicella Vaccine Revenue by Application (2020-2025)
4.1.3 Global Varicella Vaccine Price by Application (2020-2025)
4.2 Global Varicella Vaccine Market Estimates and Forecasts by Application (2026-2031)
4.2.1 Global Varicella Vaccine Sales Forecast by Application (2026-2031)
4.2.2 Global Varicella Vaccine Revenue Forecast by Application (2026-2031)
4.2.3 Global Varicella Vaccine Price Forecast by Application (2026-2031)
4.3 New Sources of Growth in Varicella Vaccine Application
5 Competition Landscape by Players
5.1 Global Varicella Vaccine Sales by Players (2020-2025)
5.2 Global Top Varicella Vaccine Players by Revenue (2020-2025)
5.3 Global Varicella Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Varicella Vaccine as of 2024)
5.4 Global Varicella Vaccine Average Price by Company (2020-2025)
5.5 Global Key Manufacturers of Varicella Vaccine, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Varicella Vaccine, Product Type & Application
5.7 Global Key Manufacturers of Varicella Vaccine, Date of Enter into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Varicella Vaccine Sales by Company
6.1.1.1 North America Varicella Vaccine Sales by Company (2020-2025)
6.1.1.2 North America Varicella Vaccine Revenue by Company (2020-2025)
6.1.2 North America Varicella Vaccine Sales Breakdown by Type (2020-2025)
6.1.3 North America Varicella Vaccine Sales Breakdown by Application (2020-2025)
6.1.4 North America Varicella Vaccine Major Customer
6.1.5 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Varicella Vaccine Sales by Company
6.2.1.1 Europe Varicella Vaccine Sales by Company (2020-2025)
6.2.1.2 Europe Varicella Vaccine Revenue by Company (2020-2025)
6.2.2 Europe Varicella Vaccine Sales Breakdown by Type (2020-2025)
6.2.3 Europe Varicella Vaccine Sales Breakdown by Application (2020-2025)
6.2.4 Europe Varicella Vaccine Major Customer
6.2.5 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments, Downstream and Major Customers
6.3.1 China Varicella Vaccine Sales by Company
6.3.1.1 China Varicella Vaccine Sales by Company (2020-2025)
6.3.1.2 China Varicella Vaccine Revenue by Company (2020-2025)
6.3.2 China Varicella Vaccine Sales Breakdown by Type (2020-2025)
6.3.3 China Varicella Vaccine Sales Breakdown by Application (2020-2025)
6.3.4 China Varicella Vaccine Major Customer
6.3.5 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments, Downstream and Major Customers
6.4.1 Japan Varicella Vaccine Sales by Company
6.4.1.1 Japan Varicella Vaccine Sales by Company (2020-2025)
6.4.1.2 Japan Varicella Vaccine Revenue by Company (2020-2025)
6.4.2 Japan Varicella Vaccine Sales Breakdown by Type (2020-2025)
6.4.3 Japan Varicella Vaccine Sales Breakdown by Application (2020-2025)
6.4.4 Japan Varicella Vaccine Major Customer
6.4.5 Japan Market Trend and Opportunities
6.5 South Korea Market: Players, Segments, Downstream and Major Customers
6.5.1 South Korea Varicella Vaccine Sales by Company
6.5.1.1 South Korea Varicella Vaccine Sales by Company (2020-2025)
6.5.1.2 South Korea Varicella Vaccine Revenue by Company (2020-2025)
6.5.2 South Korea Varicella Vaccine Sales Breakdown by Type (2020-2025)
6.5.3 South Korea Varicella Vaccine Sales Breakdown by Application (2020-2025)
6.5.4 South Korea Varicella Vaccine Major Customer
6.5.5 South Korea Market Trend and Opportunities
7 Company Profiles and Key Figures
7.1 Merck
7.1.1 Merck Company Information
7.1.2 Merck Business Overview
7.1.3 Merck Varicella Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.1.4 Merck Varicella Vaccine Products Offered
7.1.5 Merck Recent Development
7.2 GSK
7.2.1 GSK Company Information
7.2.2 GSK Business Overview
7.2.3 GSK Varicella Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.2.4 GSK Varicella Vaccine Products Offered
7.2.5 GSK Recent Development
7.3 Shanghai Institute
7.3.1 Shanghai Institute Company Information
7.3.2 Shanghai Institute Business Overview
7.3.3 Shanghai Institute Varicella Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.3.4 Shanghai Institute Varicella Vaccine Products Offered
7.3.5 Shanghai Institute Recent Development
7.4 BCHT
7.4.1 BCHT Company Information
7.4.2 BCHT Business Overview
7.4.3 BCHT Varicella Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.4.4 BCHT Varicella Vaccine Products Offered
7.4.5 BCHT Recent Development
7.5 Changsheng
7.5.1 Changsheng Company Information
7.5.2 Changsheng Business Overview
7.5.3 Changsheng Varicella Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.5.4 Changsheng Varicella Vaccine Products Offered
7.5.5 Changsheng Recent Development
7.6 Keygen
7.6.1 Keygen Company Information
7.6.2 Keygen Business Overview
7.6.3 Keygen Varicella Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.6.4 Keygen Varicella Vaccine Products Offered
7.6.5 Keygen Recent Development
7.7 Green Cross
7.7.1 Green Cross Company Information
7.7.2 Green Cross Business Overview
7.7.3 Green Cross Varicella Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.7.4 Green Cross Varicella Vaccine Products Offered
7.7.5 Green Cross Recent Development
7.8 Biken
7.8.1 Biken Company Information
7.8.2 Biken Business Overview
7.8.3 Biken Varicella Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.8.4 Biken Varicella Vaccine Products Offered
7.8.5 Biken Recent Development
8 Varicella Vaccine Manufacturing Cost Analysis
8.1 Varicella Vaccine Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Varicella Vaccine
8.4 Varicella Vaccine Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.2 Varicella Vaccine Distributors List
9.3 Varicella Vaccine Customers
10 Varicella Vaccine Market Dynamics
10.1 Varicella Vaccine Industry Trends
10.2 Varicella Vaccine Market Drivers
10.3 Varicella Vaccine Market Challenges
10.4 Varicella Vaccine Market Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Global Varicella Vaccine Sales (US$ Million) Growth Rate by Type (2020 & 2024 & 2031)
Table 2. Global Varicella Vaccine Sales (US$ Million) Comparison by Application (2020 & 2024 & 2031)
Table 3. Global Market Varicella Vaccine Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Varicella Vaccine Sales (M Doses) by Region (2020-2025)
Table 5. Global Varicella Vaccine Sales Market Share by Region (2020-2025)
Table 6. Global Varicella Vaccine Revenue (US$ Million) Market Share by Region (2020-2025)
Table 7. Global Varicella Vaccine Revenue Share by Region (2020-2025)
Table 8. Global Varicella Vaccine Sales (M Doses) Forecast by Region (2026-2031)
Table 9. Global Varicella Vaccine Sales Market Share Forecast by Region (2026-2031)
Table 10. Global Varicella Vaccine Revenue (US$ Million) Forecast by Region (2026-2031)
Table 11. Global Varicella Vaccine Revenue Share Forecast by Region (2026-2031)
Table 12. Global Varicella Vaccine Sales by Type (M Doses) & (2020-2025)
Table 13. Global Varicella Vaccine Sales Share by Type (2020-2025)
Table 14. Global Varicella Vaccine Revenue by Type (US$ Million) & (2020-2025)
Table 15. Global Varicella Vaccine Price by Type (USD/Dose) & (2020-2025)
Table 16. Global Varicella Vaccine Sales by Type (M Doses) & (2026-2031)
Table 17. Global Varicella Vaccine Revenue by Type (US$ Million) & (2026-2031)
Table 18. Global Varicella Vaccine Price by Type (USD/Dose) & (2026-2031)
Table 19. Representative Players of Each Type
Table 20. Global Varicella Vaccine Sales by Application (M Doses) & (2020-2025)
Table 21. Global Varicella Vaccine Sales Share by Application (2020-2025)
Table 22. Global Varicella Vaccine Revenue by Application (US$ Million) & (2020-2025)
Table 23. Global Varicella Vaccine Price by Application (USD/Dose) & (2020-2025)
Table 24. Global Varicella Vaccine Sales by Application (M Doses) & (2026-2031)
Table 25. Global Varicella Vaccine Revenue Market Share by Application (US$ Million) & (2026-2031)
Table 26. Global Varicella Vaccine Price by Application (USD/Dose) & (2026-2031)
Table 27. New Sources of Growth in Varicella Vaccine Application
Table 28. Global Varicella Vaccine Sales by Company (M Doses) & (2020-2025)
Table 29. Global Varicella Vaccine Sales Share by Company (2020-2025)
Table 30. Global Varicella Vaccine Revenue by Company (US$ Million) & (2020-2025)
Table 31. Global Varicella Vaccine Revenue Share by Company (2020-2025)
Table 32. Global Varicella Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Varicella Vaccine as of 2024)
Table 33. Global Market Varicella Vaccine Average Price by Company (USD/Dose) & (2020-2025)
Table 34. Global Key Manufacturers of Varicella Vaccine, Manufacturing Sites & Headquarters
Table 35. Global Key Manufacturers of Varicella Vaccine, Product Type & Application
Table 36. Global Key Manufacturers of Varicella Vaccine, Date of Enter into This Industry
Table 37. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 38. North America Varicella Vaccine Sales by Company (2020-2025) & (M Doses)
Table 39. North America Varicella Vaccine Sales Market Share by Company (2020-2025)
Table 40. North America Varicella Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 41. North America Varicella Vaccine Revenue Market Share by Company (2020-2025)
Table 42. North America Varicella Vaccine Sales by Type (2020-2025) & (M Doses)
Table 43. North America Varicella Vaccine Sales Market Share by Type (2020-2025)
Table 44. North America Varicella Vaccine Sales by Application (2020-2025) & (M Doses)
Table 45. North America Varicella Vaccine Sales Market Share by Application (2020-2025)
Table 46. Europe Varicella Vaccine Sales by Company (2020-2025) & (M Doses)
Table 47. Europe Varicella Vaccine Sales Market Share by Company (2020-2025)
Table 48. Europe Varicella Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 49. Europe Varicella Vaccine Revenue Market Share by Company (2020-2025)
Table 50. Europe Varicella Vaccine Sales by Type (2020-2025) & (M Doses)
Table 51. Europe Varicella Vaccine Sales Market Share by Type (2020-2025)
Table 52. Europe Varicella Vaccine Sales by Application (2020-2025) & (M Doses)
Table 53. Europe Varicella Vaccine Sales Market Share by Application (2020-2025)
Table 54. China Varicella Vaccine Sales by Company (2020-2025) & (M Doses)
Table 55. China Varicella Vaccine Sales Market Share by Company (2020-2025)
Table 56. China Varicella Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 57. China Varicella Vaccine Revenue Market Share by Company (2020-2025)
Table 58. China Varicella Vaccine Sales by Type (2020-2025) & (M Doses)
Table 59. China Varicella Vaccine Sales Market Share by Type (2020-2025)
Table 60. China Varicella Vaccine Sales by Application (2020-2025) & (M Doses)
Table 61. China Varicella Vaccine Sales Market Share by Application (2020-2025)
Table 62. Japan Varicella Vaccine Sales by Company (2020-2025) & (M Doses)
Table 63. Japan Varicella Vaccine Sales Market Share by Company (2020-2025)
Table 64. Japan Varicella Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 65. Japan Varicella Vaccine Revenue Market Share by Company (2020-2025)
Table 66. Japan Varicella Vaccine Sales by Type (2020-2025) & (M Doses)
Table 67. Japan Varicella Vaccine Sales Market Share by Type (2020-2025)
Table 68. Japan Varicella Vaccine Sales by Application (2020-2025) & (M Doses)
Table 69. Japan Varicella Vaccine Sales Market Share by Application (2020-2025)
Table 70. South Korea Varicella Vaccine Sales by Company (2020-2025) & (M Doses)
Table 71. South Korea Varicella Vaccine Sales Market Share by Company (2020-2025)
Table 72. South Korea Varicella Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 73. South Korea Varicella Vaccine Revenue Market Share by Company (2020-2025)
Table 74. South Korea Varicella Vaccine Sales by Type (2020-2025) & (M Doses)
Table 75. South Korea Varicella Vaccine Sales Market Share by Type (2020-2025)
Table 76. South Korea Varicella Vaccine Sales by Application (2020-2025) & (M Doses)
Table 77. South Korea Varicella Vaccine Sales Market Share by Application (2020-2025)
Table 78. Merck Company Information
Table 79. Merck Description and Business Overview
Table 80. Merck Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 81. Merck Varicella Vaccine Product
Table 82. Merck Recent Development
Table 83. GSK Company Information
Table 84. GSK Description and Business Overview
Table 85. GSK Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 86. GSK Varicella Vaccine Product
Table 87. GSK Recent Development
Table 88. Shanghai Institute Company Information
Table 89. Shanghai Institute Description and Business Overview
Table 90. Shanghai Institute Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 91. Shanghai Institute Varicella Vaccine Product
Table 92. Shanghai Institute Recent Development
Table 93. BCHT Company Information
Table 94. BCHT Description and Business Overview
Table 95. BCHT Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 96. BCHT Varicella Vaccine Product
Table 97. BCHT Recent Development
Table 98. Changsheng Company Information
Table 99. Changsheng Description and Business Overview
Table 100. Changsheng Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 101. Changsheng Varicella Vaccine Product
Table 102. Changsheng Recent Development
Table 103. Keygen Company Information
Table 104. Keygen Description and Business Overview
Table 105. Keygen Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 106. Keygen Varicella Vaccine Product
Table 107. Keygen Recent Development
Table 108. Green Cross Company Information
Table 109. Green Cross Description and Business Overview
Table 110. Green Cross Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 111. Green Cross Varicella Vaccine Product
Table 112. Green Cross Recent Development
Table 113. Biken Company Information
Table 114. Biken Description and Business Overview
Table 115. Biken Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 116. Biken Varicella Vaccine Product
Table 117. Biken Recent Development
Table 118. Production Base and Market Concentration Rate of Raw Material
Table 119. Key Suppliers of Raw Materials
Table 120. Varicella Vaccine Distributors List
Table 121. Varicella Vaccine Customers List
Table 122. Varicella Vaccine Market Trends
Table 123. Varicella Vaccine Market Drivers
Table 124. Varicella Vaccine Market Challenges
Table 125. Varicella Vaccine Market Restraints
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Varicella Vaccine Product Picture
Figure 2. Global Varicella Vaccine Sales (US$ Million) by Type (2020 & 2024 & 2031)
Figure 3. Global Varicella Vaccine Sales Market Share by Type in 2024 & 2031
Figure 4. Injection Product Picture
Figure 5. Freeze-Dried Powder Product Picture
Figure 6. Global Varicella Vaccine Sales (US$ Million) by Application (2020 & 2024 & 2031)
Figure 7. Global Varicella Vaccine Sales Market Share by Application in 2024 & 2031
Figure 8. Kids Injection Examples
Figure 9. Adults Injection Examples
Figure 10. Global Varicella Vaccine Sales, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Varicella Vaccine Sales Growth Rate (2020-2031) & (US$ Million)
Figure 12. Global Varicella Vaccine Sales (M Doses) Growth Rate (2020-2031)
Figure 13. Global Varicella Vaccine Price Trends Growth Rate (2020-2031) & (USD/Dose)
Figure 14. Varicella Vaccine Report Years Considered
Figure 15. Global Market Varicella Vaccine Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Figure 16. Global Varicella Vaccine Revenue Market Share by Region: 2020 VS 2024
Figure 17. North America Varicella Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 18. North America Varicella Vaccine Sales (M Doses) Growth Rate (2020-2031)
Figure 19. Europe Varicella Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 20. Europe Varicella Vaccine Sales (M Doses) Growth Rate (2020-2031)
Figure 21. China Varicella Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 22. China Varicella Vaccine Sales (M Doses) Growth Rate (2020-2031)
Figure 23. Japan Varicella Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 24. Japan Varicella Vaccine Sales (M Doses) Growth Rate (2020-2031)
Figure 25. South Korea Varicella Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 26. South Korea Varicella Vaccine Sales (M Doses) Growth Rate (2020-2031)
Figure 27. Global Varicella Vaccine Revenue Share by Type (2020-2025)
Figure 28. Global Varicella Vaccine Sales Share by Type (2026-2031)
Figure 29. Global Varicella Vaccine Revenue Share by Type (2026-2031)
Figure 30. Global Varicella Vaccine Revenue Share by Application (2020-2025)
Figure 31. Global Varicella Vaccine Revenue Growth Rate by Application in 2020 & 2024
Figure 32. Global Varicella Vaccine Sales Share by Application (2026-2031)
Figure 33. Global Varicella Vaccine Revenue Share by Application (2026-2031)
Figure 34. Global Varicella Vaccine Sales Share by Company (2024)
Figure 35. Global Varicella Vaccine Revenue Share by Company (2024)
Figure 36. Global 5 Largest Varicella Vaccine Players Market Share by Revenue in Varicella Vaccine: 2020 & 2024
Figure 37. Varicella Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 38. Manufacturing Cost Structure of Varicella Vaccine
Figure 39. Manufacturing Process Analysis of Varicella Vaccine
Figure 40. Varicella Vaccine Industrial Chain
Figure 41. Channels of Distribution (Direct Vs Distribution)
Figure 42. Distributors Profiles
Figure 43. Bottom-up and Top-down Approaches for This Report
Figure 44. Data Triangulation
Figure 45. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which region is expected to have the highest market share?
For each regional market, the report conducted in-depth comparative analysis from multiple dimensions such as market size, 7.8% compound annual growth rate, market demand, industrial structure, policy environment, and the layout of major enterprises. It systematically summarized the market characteristics and competitive environment of different regions. At the same time, it also focused on analyzing the demand structure, market growth drivers, and investment environment of each region, providing valuable references for enterprises to identify key regional markets, formulate global market layouts and sales strategies.
What is the annual compound growth rate of the global Varicella Vaccine market size from 2025 to 2031?
Which companies rank high in the global Varicella Vaccine market?
What was the global market size of Varicella Vaccine in 2025?
What was the global market size of Varicella Vaccine in 2031?
Related Reports
Global Varicella Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Varicella Vaccine market size was US$ 5185 million in 2025 and is forecast to reach a readjusted size of US$ 8708 million by 2032 with a CAGR of 7.8% during the forecast period 2026-2032.
Published Date: 2026-01-04
Pages: 79
USD 4250.00
(Single User License)
Global Varicella Vaccine Market Research Report 2026
The global Varicella Vaccine market was valued at US$ 5185 million in 2025 and is anticipated to reach US$ 8708 million by 2032, at a CAGR of 7.8% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 114
USD 2900.00
(Single User License)
Varicella Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Varicella Vaccine was estimated to be worth US$ 5185 million in 2025 and is projected to reach US$ 8708 million, growing at a CAGR of 7.8% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 96
USD 3950.00
(Single User License)
Global Varicella Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Varicella Vaccine market is projected to grow from US$ 4845 million in 2024 to US$ 8137 million by 2031, at a CAGR of 7.8% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-09-11
Pages: 149
USD 4900.00
(Single User License)
Global Varicella Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Varicella Vaccine was estimated to be worth US$ 4845 million and is forecast to reach approximately US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published Date: 2025-03-28
Pages: 135
USD 5900.00
(Single User License)
Varicella Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Varicella Vaccine was estimated to be worth US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 95
USD 3950.00
(Single User License)
Global Varicella Vaccine Market Research Report 2025
The global market for Varicella Vaccine was valued at US$ 4845 million in the year 2024 and is projected to reach a revised size of US$ 8137 million by 2031, growing at a CAGR of 7.8% during the forecast period.
Published Date: 2025-01-16
Pages: 80
USD 2900.00
(Single User License)
Global Varicella Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published Date: 2024-04-17
Pages: 140
USD 5600.00
(Single User License)
Global Varicella Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published Date: 2024-04-16
Pages: 130
USD 5900.00
(Single User License)
Global Varicella Vaccine Market Insights, Forecast to 2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published Date: 2024-04-07
Pages: 87
USD 4900.00
(Single User License)
Global Varicella Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Varicella Vaccine market size was US$ 5185 million in 2025 and is forecast to reach a readjusted size of US$ 8708 million by 2032 with a CAGR of 7.8% during the forecast period 2026-2032.
Published: 2026-01-04
Pages: 79
USD 4250.00 (Single User License)Global Varicella Vaccine Market Research Report 2026
The global Varicella Vaccine market was valued at US$ 5185 million in 2025 and is anticipated to reach US$ 8708 million by 2032, at a CAGR of 7.8% from 2026 to 2032.
Published: 2026-01-04
Pages: 114
USD 2900.00 (Single User License)Varicella Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Varicella Vaccine was estimated to be worth US$ 5185 million in 2025 and is projected to reach US$ 8708 million, growing at a CAGR of 7.8% from 2026 to 2032.
Published: 2026-01-04
Pages: 96
USD 3950.00 (Single User License)Global Varicella Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Varicella Vaccine market is projected to grow from US$ 4845 million in 2024 to US$ 8137 million by 2031, at a CAGR of 7.8% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-09-11
Pages: 149
USD 4900.00 (Single User License)Global Varicella Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Varicella Vaccine was estimated to be worth US$ 4845 million and is forecast to reach approximately US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published: 2025-03-28
Pages: 135
USD 5900.00 (Single User License)Varicella Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Varicella Vaccine was estimated to be worth US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 95
USD 3950.00 (Single User License)Global Varicella Vaccine Market Research Report 2025
The global market for Varicella Vaccine was valued at US$ 4845 million in the year 2024 and is projected to reach a revised size of US$ 8137 million by 2031, growing at a CAGR of 7.8% during the forecast period.
Published: 2025-01-16
Pages: 80
USD 2900.00 (Single User License)Global Varicella Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published: 2024-04-17
Pages: 140
USD 5600.00 (Single User License)Global Varicella Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published: 2024-04-16
Pages: 130
USD 5900.00 (Single User License)Global Varicella Vaccine Market Insights, Forecast to 2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published: 2024-04-07
Pages: 87
USD 4900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4250.00
USD 6375.00
USD 8500.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now